10 Jun Pembrolizumab – Keytruda- Shows Promise in Subset of Triple Negative Breast Cancer
MedicalResearch.com Interview with:
Sylvia Adams, MD
Associate Professor of Medicine
Breast Cancer and Cancer Immunotherapy Programs
NYU Langone Medical Center
Cancer Institute/Clinical Cancer Center
New York, NY 10016
MedicalResearch.com: What is the background for the Keynote-086 trial ? What are the main findings?
Response: This study is the largest immunotherapy study to date presented in metastatic triple negative breast cancer. This phase 2 trial studied the efficacy and safety of pembrolizumab (P) as single agent in a very aggressive disease and had two cohorts, a cohort of previously untreated patients (Cohort B) and a cohort with patients who had received prior chemotherapy lines in the metastatic setting (Cohort A).
The study showed that single agent pembrolizumab can elicit durable responses in a subset of patients. This was found regardless of tumoral PD-L1 expression but appeared to be much more frequent in women without prior chemotherapy treatments in the metastatic setting. Survival is especially promising for patients responding to therapy.
MedicalResearch.com: What should readers take away from your report?
Response: The earlier immunotherapy is offered in the disease course the greater the chance of its success.
MedicalResearch.com: What recommendations do you have for future research as a result of this study?
Response: Biomarkers are needed to enrich patients who are expected to have a high chance of response is very important, this work is ongoing. Equally important, combinations of treatments will need to be studied in this disease, especially the combination of chemo immunotherapy which can work synergistically.
Disclosures: Research was funded by Merck & Co
MedicalResearch.com: Thank you for your contribution to the MedicalResearch.com community.
Phase 2 study of pembrolizumab as first-line therapy for PD-L1–positive metastatic triple-negative breast cancer (mTNBC): Preliminary data from KEYNOTE-086 cohort B
J Clin Oncol 35, 2017 (suppl; abstr 1088)
Author(s): Sylvia Adams, Sherene Loi, Deborah Toppmeyer, David W. Cescon, Michele De Laurentiis, Rita Nanda, Eric P. Winer, Hirofumi Mukai, Kenji Tamura, Anne Armstrong, Minetta C. Liu, Hiroji Iwata, Larisa Ryvo, Pauline Wimberger, Deborah Card, Yu Ding, Vassiliki Karantza, Peter Schmid; NYU Langone Medical Center, New York, NY; Peter MacCallum Cancer Centre, Melbourne, Australia; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ; Princess Margaret Cancer Centre, Toronto, ON, Canada; Istituto Nazionale Tumori “Fondazione G.Pascale”- IRCCS, Naples, Italy; The University of Chicago, Chicago, IL; Dana-Farber Cancer Institute, Boston, MA; National Cancer Center Hospital East, Kashiwa, Japan; National Cancer Center Hospital East, Tokyo, Japan; The Christie Hospital NHS Foundation Trust, Manchester, United Kingdom; Mayo Clinic, Rochester, MN; Aichi Cancer Center Hospital, Nagoya, Japan; Sourasky Medical Center, Tel Aviv, Israel; Universitätsklinikum Carl Gustav Carus TU Dresden, Dresden, Germany; Merck & Co., Inc., Kenilworth, NJ; Barts Health NHS Trust, London, United Kingdom
Note: Content is Not intended as medical advice. Please consult your health care provider regarding your specific medical condition and questions.